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ABSTRACT Actinic keratosis (AK) is a common skin disease re-
lated to ultraviolet chronic exposure, that is now considered a 
squamous cell carcinoma in situ. Primary skin cancer prevention 
strategies should be recommended for high risk patients. There 
is a wide spectrum of treatment options available for AKs, and 
several variables should be taken into account regarding the best 
therapeutic choice for each patient. The purpose of this article is 
to review the current treatment strategies for AKs localized on 
the face and scalp, with a focus on the practical point of view that 
could be useful for choosing the best therapeutic option. The two 
main therapeutic approaches will be distinguished first: lesion-
directed and field-directed. Afterwards, the treatment based on 
clinical type and patient comorbidity will be discussed.
INTRODUCTION
Actinic keratosis (AK) is one of the most frequently 
encountered skin lesions, almost considered a squa-
mous cell carcinoma (SCC) in situ. Since there is a low 
but definite potential of progression into an invasive 
SCC, early treatment of AK is strongly recommended. 
This review will only discuss AK treatments of the face 
and scalp.
Several clinical variants have been described: the 
most common is the erythematous type, character-
ized by red skin color and scaling patches or papules 
surrounded by photo-damaged skin with telangiec-
tasia, dyschromia, and wrinkles (1); other variants in-
clude the hyperkeratotic type that may occasionally 
evolve into a cutaneous horn, and pigmented and 
lichenoid AK (Figure 1). Finally, actinic cheilitis may 
resemble the classic form of AK located on the lower 
lip or can appear like a thicker and more diffuse patch 
involving the entire lower lip. These clinical subtypes 
can be distinguished thanks to typical dermoscopic 
features (Figure 2). Regarding symptoms, tenderness, 
itchiness, and burning sensation are sometimes re-
ported (2). Ultraviolet (UV) rays are the most impor-
tant etiologic factor for AK development; they act 
both directly, inducing mutations of the p53 gene, 
and indirectly, causing immunosuppression and stro-
mal changes (3-4). Consequently, AKs mainly arise 
on chronic sun-exposed skin areas, such as the face, 
ears, neck, scalp, chest, hands, forearms, and lips. The 
most important risk factors for the development of 
AK are: fair skin type, prior history of AKs, immuno-
suppression, genetic predisposition, advanced age, 
and male gender (5-6). AK may undergo spontaneous 
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regression or may persist or progress into an invasive 
SCC. No clinical and dermoscopic features have been 
yet described that could help to predict the natural 
history of AK. The risk of progression has been esti-
mated to range from 0% to 0.53% per lesion per year, 
thus it is highly variable ranging from 1% to 20% per 
patients per year, depending on the number of AKs. 
In addition, the presence of AKs represents the main 
risk factor for non-melanoma skin cancer develop-
ment, and up to 80% of invasive SCCs arise from a 
pre-existing AK, thus an efficacious management is 
recommended (7-12).
TREATMENT OPTIONS
Treatment options for AKs are classified as lesion-
directed or field-directed, but these approaches may 
be combined (13). A number of factors should be 
taken into account to determine the best therapeutic 
choice, including cost, rapidity, efficacy, patient toler-
ability and compliance, number of lesions to treat, 
high-risk locations, lesion morphology, symptoms 
such as pain and bleeding, and previous treatment 
history (2).
Lesion-directed treatments
Among lesion-directed treatments, cryotherapy 
and curettage are recommended as first-line treat-
ment for few or isolated lesion, while laser therapy 
and excisional surgery are indicated as second line 
treatment in case of recurrence or persistence after 
therapy or in presence of suspicious lesions.
Cryotherapy
Cryotherapy with liquid nitrogen is a standard 
first-line treatment for isolated AKs, thanks to its low-
cost and invasiveness and easy administration (14). 
Cryotherapy causes selective tissue necrosis by the 
reduction of skin temperature with consequent freez-
ing of cells. The strongest indications for cryosurgery 
are single or few well-demarcated palpable or visible 
AKs (9). The procedure is highly effective, with report-
ed cure rates between 75% and 99% (15,16). Both 
spray and contact techniques have been success-
fully used and only one treatment is usually required; 
however, significant long-term recurrence rates have 
been observed due to lack of properly perilesional 
skin treatment (17,18). Pain, redness, edema, blister-
ing, and hypopigmentation are the common associ-
ated side-effects (19).
Laser therapy 
Laser therapy is an emerging treatment approach. 
Ablative laser resurfacing with either the CO2 or erbi-
um-doped:YAG (Er:YAG) lasers employs specific wave-
lengths to selectively induce thermolysis and destruc-
tion of the epidermal layer. Evidence demonstrated 
that ablative lasers are superior when compared with 
non-ablative fractional lasers in the treatment of AK, 
because the latter requires multiple treatments with 
photothermolysis (20-22). Compared with topical 5-
FU, Er:YAG laser resurfacing has shown, despite more 
side-effects, a significantly higher efficacy with a 91% 
clearance rate at one-year assessment, associated 
with a shorter healing period (20). Other studies re-
port cure rates between 58% and 100% (23,24).
Curettage, dermabrasion 
Surgical procedures are rarely employed in AK 
treatment. More frequently curettage is used in 
combination with electrocautery to destroy atypical 
keratinocytes that may have been left. Alternatively, 
dermabrasion can be used to manage superficial AKs, 
but great expertise is necessary (25-27).
Excisional surgery 
Excisional surgery is recommended when the 
clinical and dermoscopic diagnosis is uncertain or 
suggests progression into an invasive SCC. The clinical 
findings include: ulceration, induration/inflammation, 
bleeding, diameter >1 cm, rapid enlargement, and er-
ythema, while dermoscopic criteria include neovascu-
larization characterized by progressive development 
of elongated vessels, keratinization, and ulceration. 
Prospective trials on long-term efficacy of surgical ex-
cision are not available in the literature (28).
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Figure 1. Different clinical variants of actinic keratosis in 
the same patient.
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Field-directed treatments 
Field-directed therapies aim to eradicate both 
clinically visible and subclinical AKs within the treated 
area and should be preferred for the management of 
multiple AKs in individuals with significant sun-dam-
age and fair skin photo-type.
5-fluorouracil
5-fluorouracil (5-FU) is a pyrimidine analog that 
prevents cellular proliferation and leads to tumor 
cells death through the irreversible inhibition of thy-
midylate synthase. It has been used for AK treatment 
since the 1960s, with different concentrations and 
schedules (29). The standard treatment regimen dif-
fers according to concentrations: 5% 5-FU should be 
applied once or twice daily for 4 weeks or longer, 0.5% 
once daily up to 4 weeks, and 1% twice daily for up to 
6 weeks. A longer period and frequency of applica-
tion is recommended if lesions are not located on the 
head-neck region (30). Treatment with 5-FU can re-
sult in severe dermatitis, irritation, rash, xerosis, pru-
ritus, pain, and ulceration, leading to high withdrawal 
rates. Complete clearance rates range from 16.7% to 
57.8% for multiple AKs of the face and from 43% to 
100% for multiple AKs of the scalp (31). Goon et al. 
(32) proposed an off-label regimen with topical 5% 
5-FU applied in occlusion (chemowraps) that appears 
to be more effective for large areas of sun-damaged 
skin, with a low risk of systemic and local toxicity.
Recently, a new topical combination of 0.5% 5-
fluorouracil and 10% salicylic acid (5-FU/SA) applied 
once daily up to 12 weeks showed a higher complete 
clinical clearance rate and a lower AK recurrence rate 
than topical 5-FU alone, with only mild to moderate 
skin adverse effects (33).
Diclofenac sodium
Diclofenac is a nonsteroidal anti-inflammatory 
drug; the formulation of 3% diclofenac sodium in 
2.5% hyaluronic acid gel has been used for topical 
treatment of AKs since the 1990s (34). The mecha-
nism of action has not been fully clarified, but cy-
clo-oxgenase-2 pathway inhibition, inhibition of an-
giogenesis, and induction of apoptosis are probably 
involved (35). Diclofenac sodium should be applied 
twice-daily for up to 90 days; it is generally well-toler-
ated due to its low irritation power, although it may 
cause erythema, pruritus, dry skin, and scaly rash. A 
recent study showed a 75% lesion count reduction 
in 85% and 91% of patients who applied diclofenac 
sodium twice daily for 90 days, one month, and one 
year after the end of treatment, respectively [36].
Imiquimod
Imiquimod is an immune-response modifier ap-
proved for the treatment of AK of the head and neck. 
Its activity is primarily based on activation of toll-like 
receptor-7 in the epidermis; the stimulation of pro-
inflammatory cytokines results in antiviral, antitumor, 
and immune-regulatory effects (37-39). Three stud-
ies investigating different treatment regimens of 5% 
imiquimod twice per week for 16 weeks (40), 3 times 
per week for 4 weeks followed by 4 weeks of washout 
(41), and once per week for 6 months (42) indicated 
that imiquimod remain effective even at reduced ap-
plication frequencies or in a cyclical fashion. Side-ef-
fects are restricted to the site of application and in-
clude erythema, ulceration, edema, and scaling (43). 
Application of 5% imiquimod 3 times per week for 16 
weeks resulted in a complete clearance of 57.1% and 
partial clearance of 72% of lesions (44,45).
The recently approved a new formulation of 
3.75% imiquimod, administered for 2 cycle of 2-week 
daily treatment separated by a 2-week treatment-free 
interval, achieved a partial clearance in 59% of cases 
and a complete clearance in 35%, reaching 59.5% 
Figure 2. Dermoscopic images of erythematous actinic 
keratosis: red pseudo-network (A); scaling patch (B) sur-
rounded by photo-damaged skin.
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when preceded by cryotherapy. An additional week 
of treatment was not recommended since no addi-
tional benefit was shown (46-48).
Ingenol mebutate
Ingenol mebutate gel has been recently ap-
proved for the treatment of non-hypertrophic non-
hyperkeratotic AKs located on the face, scalp, trunk, 
and extremities. It has shown a dual mechanism of 
action, consisting of both chemoablative and immu-
nostimulatory effects (49). Depending on body loca-
tion, 2 different formulation are recommended: the 
0.015% gel formulation that is used once daily on the 
face or scalp for 3 consecutive days, and the 0.05% 
gel formulation which is applied once daily on the 
trunk or extremities for 2 consecutive days. A com-
plete clearance rate of 42% and lesion count reduc-
tion of 83% were reported at day 57; after 12 months 
of treatment a sustained clearance rate of 46% and 
lesion reduction rate of 87% were also achieved (50-
51). Similarly to all topical treatments, local skin re-
sponses include erythema, flaking, scaling, and crust-
ing. Moreover, thanks to the lack of phototoxic or 
photosensitizing properties, ingenol mebutate can 
be used throughout the year (52).
Since January 16, 2020, EMA has recommended 
the suspension of ingenol mebutate therapy in Eu-
ropean countries (EMA/32231/2020), as a precaution 
while review of skin cancer risk continues. Neverthe-
less, the use of ingenol mebutate in all other countries 
worldwide remains a valid therapeutic option (53).
Photodynamic therapy 
Photodynamic therapy (PDT) can be used as both 
a lesion-direct and a field-direct therapy. Topical pho-
tosensitizers are used in PDT, such as 5-aminolevu-
linic acid (5-ALA) or its ester methyl-aminolevulinate 
(MAL); these are activated by light, to produce apop-
tosis and necrosis of abnormal cells with minimal 
damage to the surrounding normal tissue. 5-ALA is 
available in 8 mg self-adhesive patch formulation, 
in 78 mg/g nanoemulsion gel, and in 20% solution, 
while MAL is disposable as 16.8% cream. After 3 
hours from the application of photosensitizer on the 
tumor surface, a 7-9 minute illumination with a blue 
or red light emitting lamp (respectively 417 nm and 
630 nm of wavelength) is performed. PDT is recom-
mended for non-hyperkeratotic, non-pigmented AKs 
with efficacy rates that vary from 70% to 90%. The 
best results are obtained after two sessions (54-58). 
Despite intense application-site pain, redness, and 
swelling as frequent photo-toxic reactions, cosmetic 
results are usually excellent. The activation of the 
photo-sensitizers obtained with daylight exposure 
(daylight PDT), achieved similar efficacy rates than 
conventional PDT, while minimizing pain and local 
inflammation (59). A new nanoemulsion-based for-
mulation of ALA called BF-200, combined with nar-
row-spectrum light illumination, has shown a greater 
clinical efficacy than MAL; in a meta-analysis of 25 tri-
als, BF-200 ALA resulted the treatment with the high-
est efficacy rate (60,61).
Chemical peels
Chemical peeling represents another suitable op-
tion for the treatment of multiple AKs of the face. Tri-
chloroacetic acid is the most commonly used, in con-
centrations varying from 35% to 70%, and satisfac-
tory results can be achieved with only one treatment 
session. Alternatively, 70% alpha-hydroxy acid or 88% 
phenol peels can be used for a deep exfoliation. They 
can be associated with PDT or cryotherapy, and effi-
cacy rates vary according to the employed acid com-
pound. Trichloroacetic acid has been shown to cause 
the disappearance of the 75% of visible AKs, although 
at 1-year follow-up the recurrence rate ranged from 
25% to 35%. Treatment with chemical peels are fre-
quently associated with pain, local erythema, and 
mild desquamation, while scarring and pigmentation 
changes may rarely occur (62,63).
Retinoids
Both topical and oral retinoids have been used 
for AK treatment, showing conflicting results. Oral 
isotretinoin, thanks to its anti-proliferative and anti-
apoptotic properties, may avoid new skin cancer 
development; it may be beneficial in patients with 
severe actinic damage with multiple and diffuse AKs. 
In case of recurrence, the combination of low-dose 
isotretinoin (10 mg/day) and 5-FU may be effective, 
as a second line therapy, in preventing the appear-
ance of new AKs and in reducing the number of exist-
ing lesions. Prolonged use of oral retinoids is limited 
by their significant adverse effects such as xerosis, 
cheilitis, conjunctivitis, elevation of transaminases, 
triglycerides, and cholesterol levels and teratogenic-
ity (64,65).
Combination therapy
Use of two different treatments concurrently or 
sequentially may improve clearance outcomes and 
must be encouraged in order to successfully manage 
AKs, especially in widespread or resistant cases. For 
example, a field-directed topical cream approach af-
ter cryotherapy was shown to be more effective than 
the use of single therapies alone (66).
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Prevention
Photo-protection remains the best way to pre-
vent the appearance of AKs. Avoidance of sun expo-
sure during the peak hours of UV emission should be 
recommended. Regular use of high sun protection 
factor sunscreens can provide protection against 
damage induced by UVs when solar exposure cannot 
be avoided. New topical sunscreens containing pho-
tolyase, a critical enzyme in DNA repair, have demon-
strated a great efficacy in reducing the UV-mediated 
cell damage. The chronical use of these products may 
lead to a 40-45% decrease of UV-inducible pyrimidine 
dimers and p-53 mutations in keratinocytes and can 
prevent the immunosuppressant effect of UV rays 
(67,68).
PRACTICAL PARAMETERS FOR  
TREATMENT CHOICE 
Treatment based on anatomic site of  
lesion
Lesion location is an important variable that can 
affect response to treatment. It is known that AKs on 
the scalp tend to be more resistant to therapy than 
lesions localized on the face, often requiring multiple 
extended treatments. Sometimes a pre-treatment 
with 5% salicylic acid is also required (69). The effec-
tiveness of PDT is poor for AK on acral sites, probably 
due to a higher proportion of thicker lesions on these 
locations. The area around the eyes and mouth re-
quires the use of a treatment with a minimal skin-irri-
tating effect such as diclofenac, which is also effective 
for AK of the lip. When the cosmetic outcome must be 
considered for lesions on the face, either imiquimod 
or PDT are generally preferable. A network meta-anal-
ysis comparing the efficacy of various available treat-
ment for AKs of the face and scalp concluded that BF-
200 ALA has the highest absolute complete clearance 
rate, followed by 0.5% and 5% 5-FU, 5% imiquimod 
for 16 weeks, 5% imiquimod for 4 weeks, and ALA-
PDT patch (70-72). Cryosurgery is contraindicated 
when the lesions are located in delicate areas such as 
the central part of the face, hairy scalp, and eyebrows, 
due to an increased risk for scarring alopecia.
Treatment based on patient comorbidities 
In elderly and disabled patients or those with 
significant comorbidities, adherence to topical field 
self-administered therapies may be an issue, and 
thus cryotherapy and PDT are more suitable options 
in these cases. Immunosuppressed patients such as 
hematopoietic/solid organ transplant recipients, pa-
tients with HIV, or those taking immunosuppressive 
drugs have a higher risk to develop AKs compared 
with the general population; additionally, AKs in these 
patients may turn into invasive SCC more quickly, and 
close monitoring for early detection of AKs and more 
rigorous treatment approaches are thus necessary. In 
immunosuppressed patients, excisional surgery is the 
first-line therapeutic choice in case of suspicious le-
sions, while for multiple AKs a combination between 
an ablative and a topical treatment is the best option. 
Conversely, in these patients imiquimod must be 
used with caution and PDT has demonstrated a lower 
clearance rate compared with immunocompetent 
patients. Finally, oral retinoids could even be a valu-
able option in immunosuppressed individuals as well 
in patients affected by xeroderma pigmentosum and 
Gorlin-Goltz syndrome (73-76).
Treatment based on clinical type of lesion
Treatment choice primarily depends on clinical 
presentation of AKs, using focal ablative procedures 
to treat single lesions and field directed treatments 
for multiple visible and non-visible lesions over a large 
sun-damaged area. Both European and Italian guide-
lines address patient classification into subgroups ac-
cording to the clinical presentation. “Single lesion” is 
defined as the presence of one to five palpable or vis-
ible AK per field or affected body region, while mul-
tiple lesions refer to six or more distinguishable AKs 
in one body region or field. European recommenda-
tions for single AK indicate only cryotherapy as a suit-
able option, while curettage, 0.5% and 5% 5-FU 5-FU/
SA, 3.75%, and 5% imiquimod and 0.015% ingenol 
mebutate and PDT are weakly recommended. No rec-
ommendations are present for 3% diclofenac and la-
ser therapy. Conversely, 0.5% 5-FU, 3.75% imiquimod, 
0.015%, and 0.5% ingenol mebutate and PDT are all 
strongly recommended for multiple AKs (9).
Treatment based on clinical grade
Lesion grade is another key parameter that can af-
fect treatment response. According to Olsen et al. (77), 
AKs are clinically classified into 3 severity degrees: (i) 
grade 1 (mild): flat pink macule or patch felt better 
than seen; (ii) grade 2 (moderate): moderately thick 
pink to red papules or plaques with a rough, hyper-
keratotic surface and variable induration that are eas-
ily seen and felt; and (iii) grade 3 (severe): very thick 
red to pigmented indurated plaques on sun-dam-
aged skin. A histological classification was also devel-
oped based on the extent of atypical keratinocytes in 
the epidermis: AK I indicates the presence of atypi-
cal keratinocytes in the lower third of the epidermis; 
in AK II atypical keratinocytes extend over the lower 
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two-thirds of the epidermis with buds of keratino-
cytes extending into the upper papillary dermis; and 
AK III indicates the diffusion of atypical keratinocytes 
in more than two-thirds of the full thickness of the 
epidermis, including the epithelia of hair follicles (78). 
Invasive SCC is believed to develop from the progres-
sive extension of atypical keratinocytes from the epi-
dermidis into the dermis. Interestingly, a recent study 
questioned the pathway of progression from AK I to 
AK III and consequently to invasive SCC by demon-
strating that invasive carcinoma generally arises from 
basaloid atypical keratinocytes of AK I; consequently, 
all grades of AK should be treated (79). Intuitively, 
thin grade 1 lesions should be more responsive to 
treatment than grade 3 lesions. Response rates for 
grade 1 lesions were higher for imiquimod and MAL-
PDT (72.13% and 71.64%, respectively) compared 
with response rates for grade 2 lesions (37.03% and 
57.89%, respectively). Due to the limited penetration 
of the photosensitizer drugs, PDT is not recommend-
ed for hyperkeratotic AKs although the removal of 
overlying crust and scale may improve efficacy. More 
invasive options are therefore suggested in grade 3 
lesions, such as dermoabrasion, curettage, double 
freeze-cryotherapy, and surgery. 
CONCLUSIONS
Although the real risk of progression from AK to 
invasive SCC is unknown, AK should be considered a 
SCC in situ and consequently treated. Optimal man-
agement should take into account the treatment of 
single lesions as well as the treatment of the entire 
field of cancerization. Given the large number of 
treatment options with advantages and disadvan-
tages, proper guidance towards their selection and 
usage is important. This review provides a global and 
complete report of main therapeutic approaches cur-
rently in use, highlighting their optimal applications 
in clinical practice.
A gold standard management algorithm is diffi-
cult to design due to the large number of variables 
that should be considered: number of lesions, local-
ization, clinical and histological features, patient age 
and comorbidities, patient compliance, and clinician’s 
experience. For that reason, the best approach would 
be sequential or combination therapies evaluated in-
dividually, which is known as patient tailored therapy, 
in order to achieve the best results for each patient.
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